CEO Jeff Roix spoke to BioCentury about how NeoPhore Ltd is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of neoantigens to turn “dark” tumors “light” that can be treated with immunotherapies.
06.08.2019
BioCentury's Emerging Company Profile
More news
16.09.2025
NeoPhore's CEO Presents at Morgan Stanley 23rd Annual Global Healthcare Conference | September 2025
NeoPhore's CEO - Michael Shih - recently presented the NeoPhore story at the Morgan Stanley Global Healthcare Conference on Monday September 8th …
16.12.2024
Neophore appoints Michael Shih as Chief Executive Officer
NeoPhore appoints Michael Shih as Chief Executive Officer Highly experienced corporate development leader with a track record of international pharma …
22.05.2024
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb Additional funding will be used to explore …